105P Prognostic value of the NTRK fusion biomarker in the Netherlands

Abstract

Neurotrophic tyrosine receptor kinase (NTRK) gene fusions involving either NTRK1, 2, or 3 are oncogenic drivers of various adult and pediatric tumor types. The corresponding tropomyosin receptor kinase (TRK) proteins are targets for precision medicines. Patients (pts) with NTRK fusion-positive (NTRK+) cancers can be treated with TRK inhibitors, for which single-arm studies have shown high response rates. However, the assessment of comparative effectiveness is challenging. Using historical data is complicated by insufficient information about the prognostic value of NTRK gene fusions, creating uncertainty about the appropriate control group.